staurosporine

Staurosporine (AM-2282) is a protein kinase inhibitor with ATP-competitive and non-selective inhibitory activity (IC50=6/15/2/3/3000 nM) against PKC, PKA, c-Fgr, phosphorylase kinase and TAOK2. Staurosporine also induces apoptosis.

Staurosporine-Boc is a natural product isolated from the actinomycete Streptomyces staurosporeus and functions as a potent, non-selective protein kinase inhibitor. It can inhibit various protein kinases, including protein kinase C (PKC), tyrosine kinase, and serine/threonine kinase. Due to its broad inhibitory profile, Staurosporine-Boc is widely used as a tool compound in biological research, particularly in the study of cell signaling pathways.

UCN-02 (7-epi-Hydroxystaurosporine) is a selective and highly potent protein kinase C (PKC) inhibitor produced by Streptomyces N-126 strain, inhibiting PKA. UCN-02 has antitumor activity.

K-252a is a protein kinase inhibitor targeting serine-threonine, tyrosine, and CAM kinases. In vitro, it blocks NGF-induced TrkA signalling and neural differentiation, exhibiting antitumour, antibacterial, anti-inflammatory, and neuroprotective activities.

K-252c is a staurosporine analog isolated from Nocardiopsis sp. and is a cell-permeable PKC inhibitor (IC50: 2.45 μM). K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase. K-252c causes apoptosis in human chronic myelogenous leukemia cancer cells.

Picroside I (6'-Cinnamoylcatalpol), a hepatoprotective agent, is reported to be antimicrobial and used against hepatitis B. It has antioxidant, and anti-inflammatory activities, it may be the valuable anti-invasive drug candidates for cancer therapy by suppressing Collagenases and Gelatinases. Picroside I can enhance basic fibroblast growth factor(bFGF)-, staurosporine- or dbc-mitogen-activated protein (MAP)-induced neurite outgrowth from PC12D cells.

1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the

Nardosinone (Standard) is a reference standard for research and analysis in studies involving Nardosinone. 1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the promotion of PKA and ERK signaling pathway. 3. Nardosinone enhances staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying both the MAP kinase-dependent and -independent signaling pathways of dbcAMP and staurosporine. 4. The enhancement of NGF-induced neurite outgrowth from PC12D cells by Nardosinone involves activation of a down-stream step of the MAP kinase-dependent cascade of NGF coupled with PKC.

Picroside I (Standard) is a reference standard for research and analysis in studies involving Picroside I. Picroside I (6'-Cinnamoylcatalpol), a hepatoprotective agent, is reported to be antimicrobial and used against hepatitis B. It has antioxidant, and anti-inflammatory activities, it may be the valuable anti-invasive drug candidates for cancer therapy by suppressing Collagenases and Gelatinases. Picroside I can enhance basic fibroblast growth factor(bFGF)-, staurosporine- or dbc-mitogen-activated protein (MAP)-induced neurite outgrowth from PC12D cells.

Co-treatment with Tanshinone IIB (TSB) significantly inhibits the DNA laddering, cytotoxicity and apoptosis of rat cortical neurons induced by staurosporine in a concentration-dependent manner; TSB also suppresses the elevated Bax protein and decreased bc

Compound 7, also known as 3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine, serves as an inhibitor of protein kinases, displaying IC50 values of 0.092 μM for PKC-α, 0.26 μM for ROCK, and 0.77 μM for ASK1. Additionally, this compound exhibits significant cytotoxicity towards PC-3 cancer cells, with an IC50 of 0.16 μM [1].